COMBI.ST
CombiGene AB (publ) [COMBI.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
COMBI.ST Stock Summary
In the News
COMBI.ST Financial details
Company Rating
-
Market Cap
78.41M
Income
-35.67M
Revenue
5.72M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
04 May 2021
P/E
-1.36
Forward P/E
-
PEG
-0.02
P/S
-5.2
P/B
0.46
P/C
-
P/FCF
-1.89
Quick Ratio
19.74
Current Ratio
20.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.8
EPS next Y
-
EPS next Q
-
EPS this Y
566.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-21.43%
Revenue last 5Y
-18.04%
Revenue Q/Q
-48.84%
EPS Q/Q
-23.81%
-
-
-
-
SMA20
2.51%
SMA50
3.38%
SMA100
-4.3%
Inst Own
-
Inst Trans
-
ROA
-32%
ROE
-30%
ROC
-0.34%
Gross Margin
100%
Oper. Margin
381%
Profit Margin
381%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.0-8.1
52W High
-67.13%
52W Low
+31.5%
RSI
63.26
Rel Volume
0.1
Avg Volume
58.8K
Volume
5.96K
Perf Week
9.58%
Perf Month
6.91%
Perf Quarter
26.44%
Perf Half Y
52.91%
-
-
-
-
Beta
1.302
-
-
Volatility
0.09%, 0.07%
Prev Close
6.48%
Price
2.63
Change
3.95%
Company Profile
- Volume Average 58.8K
- Market Capitalization 78.41M
- Employee 11
- CEO Mr. Peter Ekolind
- Headquarters Lidingö,SE
- IPO Date 2015-05-25
-
Website
https://www.combigene.com 
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
